Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

 20.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 140.00p
  • 52 Week Low: 19.50p
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 25,000
  • Market Cap: £2.73m
  • RiskGrade: 267
  • Beta: 0.43

Feedback considering opportunities for 'Bleepa' product

By Josh White

Date: Thursday 17 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Specialist medical imaging technology company Feedback updated the market on 'Bleepa' on Thursday, reporting that it was considering a number of potential opportunities for the product following its launch at the NHS Expo in September.
The AIM-traded firm said it was in "advanced discussions" with NHS pilot sites, while additionally pursuing a number of commercial opportunities within and outside the NHS, and hoped to commence Bleepa pilot schemes in the near future.

To date, the Bleepa product had been "well received" by the healthcare community, the board reported, adding that it believed that it would enable a number of healthcare providers to provide "faster, safer, more efficient" care.

"We are very encouraged by the response to Bleepa having discussed this with senior NHS executives and clinicians at NHS Expo," said chief executive officer Tom Oakley.

"The feedback that we have received is that Bleepa clearly has applications across the healthcare sector, not only in individual hospital settings but also in community and cross site clinical settings.

"We look forward to making further announcements in relation to Bleepa®, in due course."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 20.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 140.00p
52 Week Low 19.50p
Volume 25,000
Shares Issued 13.33m
Market Cap £2.73m
Beta 0.43
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average
Price Trend
91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Income Not Available
Growth
45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for 22-Nov-2024

Time Volume / Share Price
08:13 25,000 @ 20.20p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page